– For the reduction of atherosclerotic events such as myocardial infarction, stroke, or vascular death in patients with atherosclerosis documented by recent stroke, myocardial infarction, or established peripheral arterial disease.

– For treatment of patients suffering from non-ST sequel elevation, acute coronary syndrome (unstable angina or non-Q wave myocardial infarction) including patients undergoing stent placement following percutaneous coronary intervention or combination with ASA in medically treated patients eligible from thrombolytic therapy.